 |
Return Create A Forum - Home |
 |
--------------------------------------------------------- |
|
MS Speaks |
 |
https://msspeaks.createaforum.com |
|
--------------------------------------------------------- |
|
***************************************************** |
|
Return to: OCREVUS (ocrelizumab) |
|
***************************************************** |
|
#Post#: 2983-------------------------------------------------- |
|
Higher severe COVID-19 risk for patients on Ocrevus, Rituxan |
|
By: agate Date: July 31, 2020, 11:47 am |
|
--------------------------------------------------------- |
|
From MS Focus (July 24, 2020)--"Higher severe COVID-19 risk for |
|
patients on Ocrevus, Rituxan." The article quotes Dr. Ben |
|
Thrower, well known in MS research, as saying that the risk of |
|
taking MS disease-modifying therapy (DMT) still outweighs the |
|
benefits, however. |
|
https://msfocus.org/About-Us/MSF-News-Articles/2279 |
|
#Post#: 3278-------------------------------------------------- |
|
(Abst.) COVID-19 in ocrelizumab-treated people w/MS |
|
By: agate Date: May 4, 2021, 1:46 am |
|
--------------------------------------------------------- |
|
Might this be a drug company's response to the reports about a |
|
higher risk for severe COVID-19 in patients on Ocrevus? From |
|
PubMed, "COVID-19 in ocrelizumab-treated people with multiple |
|
sclerosis" (April 2021): |
|
https://pubmed.ncbi.nlm.nih.gov/33482590/ |
|
***************************************************** |
